)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Pliant Therapeutics (PLRX) investor relations material
Pliant Therapeutics Piper Sandler 37th Annual Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Piper Sandler 37th Annual Healthcare Conference summary4 Dec, 2025
Key data highlights
Phase 1 study of PLN-101095, an oral dual integrin inhibitor, showed durable responses with a median of 15 months on treatment and four responders, including one complete responder in a heavily pretreated, diverse patient population.
60% of ICI secondary refractory participants experienced disease stabilization or tumor reduction, with a median treatment duration of 10 months.
Interferon gamma signal distinguished responders from non-responders and was statistically significant after 14 days of monotherapy, with IFN-γ emerging as a potential early biomarker.
Safety profile was favorable, with rash as the most common mild or moderate adverse event, and only one discontinuation.
Compared to interim data, there is now one additional responder and a previous partial responder has become a complete responder.
Program advancement and next steps
The program will advance to a phase 1b study, focusing on non-small cell lung carcinoma and other tumor types, with expansion cohorts planned for 2026.
The 1,000-mg BID dose will be evaluated, with monotherapy arms retained to further explore biomarker effects.
Cohort size for phase 1b will be manageable and easily executable.
Data from the next phase are anticipated in 2027, depending on cohort size and study design.
Patient mix will be informed by ongoing data analysis to optimize for responders.
Mechanism and platform potential
PLN-101095 selectively blocks αvβ8 and αvβ1 integrin-mediated TGF-β activation, modulating the tumor microenvironment and enhancing T cell IFN-γ effector function.
The mechanism shifts tumors to a high IFN-γ, ICI-responsive state, resensitizing them to anti-PD-(L)1 therapies.
Integrins are validated targets for both modulation and cell-selective drug delivery, with a 15,000+ compound library supporting broad platform applications.
The platform includes emerging cell-specific delivery for siRNA payloads, with broad disease applicability.
Additional biomarker data are being analyzed, with plans to present more at future conferences.
How will interferon gamma guide 10-10-95 development?
What's the strategy for new platform assets?
Small molecule advantage vs. antibody competitors?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Pliant Therapeutics earnings date
Q4 20252 Mar, 2026
Next Pliant Therapeutics earnings date
Q4 20252 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Pliant Therapeutics, Inc. (PTI) is a clinical stage biopharmaceutical company developing DNA-based therapeutics that enable patients to reverse fibrosis and related diseases. The company's lead product candidate, PRTX-100, is a proprietary plasmid DNA therapeutic that has completed Phase 2 testing in nonalcoholic steatohepatitis (NASH). PTI owns the rights to exclusive plasmid-based therapies optimized for solid tumors including breast and pancreatic cancers. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage